BeyondSpring (BYSI) Stock Price, News & Analysis

Company Overview

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research centers on treatments designed to improve outcomes for patients receiving chemotherapy and to enhance the body’s immune response against tumors.

BeyondSpring’s lead product candidate is plinabulin, also known as BPI-2358 or NPI-2358. Plinabulin is a small-molecule therapy being studied for the prevention of chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells, as well as for possible use in oncology treatment combinations. The company has also investigated plinabulin in combination with other cancer therapies and across multiple tumor types.

Founded in 2010, BeyondSpring has conducted clinical development activities in the United States and China, among other international markets. The company was led by co-founder Lan Huang, who has served as chief executive officer and chairman. BeyondSpring’s programs have progressed through clinical testing and regulatory review, although the development and approval status of individual candidates may change as the company receives additional regulatory and clinical feedback.

Key Stats

• Today's Range: $0.59 to $0.67
• 50-Day Range: $0.60 to $1.17
• 52-Week Range: $0.57 to $2.44
• Volume: 57,680 shs
• Average Volume: 588,387 shs
• Market Capitalization: $24.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

BeyondSpring Stock Analysis - MarketRank™

BeyondSpring scored higher than 7% of companies evaluated by MarketBeat, and ranked 871st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

BeyondSpring has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

BeyondSpring has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BeyondSpring is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeyondSpring is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.41% of the float of BeyondSpring has been sold short.

Short Interest Ratio / Days to Cover

BeyondSpring has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BeyondSpring has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeyondSpring does not currently pay a dividend.

Dividend Growth

BeyondSpring does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.08

News Sentiment

BeyondSpring has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for BeyondSpring this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BeyondSpring insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.31% of the stock of BeyondSpring is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.29% of the stock of BeyondSpring is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BYSI
• CIK: 1677940
• Web: www.beyondspringpharma.com
• Phone: (646) 528-4184
• Fax: 1-646-882-4228
• Employees: 44
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.01 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -28.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.70
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 14.23
• Cash Flow: $0.11 per share
• Price / Cash Flow: 5.36
• Book Value: ($0.59) per share
• Price / Book: -1.03

Miscellaneous

• Outstanding Shares: 41,120,000
• Free Float: 29,068,000
• Market Cap: $24.90 million
• Optionable: Optionable
• Beta: -0.21